BOSTON — New Endocrine Society guidelines call for limiting vitamin D supplementation beyond the daily recommended intake to specific risk groups and advises against routine 25-hydroxyvitamin D [25(OH)D] testing in healthy individuals. The evidence-based document was presented on June 3, 2024 at the Endocrine Society annual meeting and simultaneously published in the Journal of Clinical …
When the American Cancer Society recently unveiled changes to its lung cancer screening guidance, the aim was to remove barriers to screening and catch more cancers in high-risk people earlier. Although the lung cancer death rate has declined significantly over the past few decades, lung cancer remains the leading cause of cancer deaths worldwide. Detecting …
Continuing a tumor necrosis factor inhibitor (TNFi) during pregnancy does not increase risk of worse fetal or obstetric outcomes, according to new research presented at the American College of Rheumatology (ACR) 2023 Annual Meeting. Patients who continued a TNFi also had fewer severe infections requiring hospitalization, compared with those who stopped taking the medication during …
When Christopher Rajkumar, MD, presented the positive results of ORBITA-2, the second placebo-controlled trial of percutaneous coronary intervention (PCI) in stable angina, you could almost feel the relief of cardiologists at the American Heart Association meeting. All is right again. Thank goodness. The first ORBITA trial stunned our community when it showed that PCI compared …
PHILADELPHIA — Percutaneous coronary intervention (PCI) in patients with stable coronary artery disease (CAD) reduces angina frequency, increases exercise capacity, and improves quality of life, results of a placebo-controlled, randomized trial show, confirming advantages that have never before been proven. “The effect of PCI was immediate, sustained over 12 weeks, and consistent across all endpoints,” …